Boehringer Mannheim Gmbh

Amsilk Gmbh

Hoffmann-la Roche Inc.

Roche Diagnostics Gmbh

Ludwig-maximilians-universitat München

Universität Bayreuth

Other

Abbvie Inc.

Medigene Ag

Abbvie Biotechnology Ltd

Abbott Laboratories Corporation

Abbott Biotechnology Ltd.

F. Hoffmann-la Roche Ag

Hypharm Gmbh

Syncore Biotechnology Co., Ltd.

Gerhard Winter

Heinrich Woog

Wolfgang Fraunhofer

David Wayne Borhani

Julia Engert

Stefan Gottschalk

Hans-Juergen Krause

Uwe Michaelis

Anette Koenigsdorfer

Thomas Scheibel

Lin Romer

Ute Slotta

Heinrich Haas

Michael Teifel

Thomas Fichert

Toralf Peymann

Stefan Hepbildikler

Wolfgang Kuhne

Christian Welz

Friedrich Gruber

Eva Rosenberg

Brita Schulze

Carsten Mundus

Matthias Lucke

Rainer Rudolph

Peter Lell

Werner Gruber

Fritz Demmer

Hans-Peter Haar

Rolf-Dieter Gabel

Sonja Molinaro

Klaus Hellerbrand

Hans Koll

Lin Römer

Oliver Schramel

Markus Mattern

Cihad Anamur

Christian Fellner

Alexander Wirl

Achim Goepferich

Thomas Kissel

Bernhard Pichler

Wolfgang Roedel

Wolfgang Mutter

Hans-Jorg Markl

Martin Schwab

Werner Heller

Georg Kallmeyer

Sebastian Fuchs

Conrad Coester

Simon Eisele

George Bevan Meacham

Elisa Agostini

Andreas Lammel

Markus Hofer

Julia Myschik

Weiwei Tian

Christian Klessen

Petra Bastian

Rainer Bader

Heidrun Gehlen

Michael Morlock

John Klier

Hans-J&ouml;rg Markl

Appollon Papadimitriou

Manfred Beuttenmueller

Sandra Schulze

Martin Brandl

David W Borhani

The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.

Articles comprising a silk polypeptide for antigen delivery

The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coated silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films.

Coated silk films, methods for the production thereof and uses thereof

The invention relates to a needleless injection device or a device for the needleless injection of a substance into a tissue or body, with which device a substance, in particular an active substance, can be injected by means of high pressure. A device according to the invention comprises a chamber () containing a pyrotechnic material, wherein the chamber has a fixed double membrane () at a discharge opening, wherein the skin-side membrane () of the double membrane () is provided with a substance application (). A successful injection lies in the fact that sufficient substance is introduced into the body through the tissue barrier or body barrier, in particular such as the skin.

Needleless injection device with double membrane

For the removal of high molecular weight compounds from recombinantly produced polypeptides generally chromatographic methods are employed. It has been found that underivatized controlled pore glass (uCPG) selectively binds high molecular weight compounds present in a solution. The purified polypeptide can be recovered e.g. from the flow through of a chromatography column containing uCPG as chromatography material. It has been found that this effect is pronounced at a pH value of about 4 to 6 in buffered solutions. With approximately 100 mto 150 muCPG surface per g of polypeptide almost 80% to 95% of the high molecular weight compounds are removed with a yield of 80% to 90% of polypeptide.

Immunoglobulin aggregate removal

The invention relates to a needleless injection device, comprising a firing chamber () for the needleless injection of a substance (), having a firing chamber containing a pyrotechnic material and a gel-like medium, with which a substance, in particular an active substance, can be accelerated at high speed and injected in a needleless manner into a tissue or into a body by means of a membrane (). The invention also relates to a method for producing a needleless injection device of this type containing a firing chamber together with pyrotechnic material and filled with a gel-like medium, and use thereof.

Needleless injection device having a gel and a membrane

The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and/or treatment of an allergic and/or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect.

Immunomodulating nanoparticulate composition

A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Method of producing a cationic liposomal preparation comprising a lipophilic compound

The present invention relates to a method of producing and loading silk particles, preferably spider silk particles, with a compound. In particular, the present invention provides a novel two step method for loading silk particles, preferably spider silk particles, with small and water-soluble compounds. Also disclosed are silk particles, preferably spider silk particles, loaded with at least one compound which are eminently suited as carriers for controlled and sustained delivery applications. Furthermore, the invention relates to pharmaceutical or cosmetic compositions comprising said silk particles, preferably spider silk particles, and a pharmaceutically active compound or cosmetic compound for controlled and sustained release. The present invention is also directed to silk particles, preferably spider silk particles, loaded with a compound obtainable by the method according to the invention.

Silk particles for controlled and sustained delivery of compounds

The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.

Crystalline anti-human IL-12 antibodies

Herein is reported a tangential flow filtration method with a pre-filtration solute concentration adjustment in order to ensure a defined concentration of the components of the solution after tangential flow filtration.

Pre-filtration adjustment of buffer solutes

The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.

Crystalline anti-hTNFalpha antibodies

Growing community of inventors

Penzberg, Germany

Gerhard Winter